Oncology Central

EGFR mutations in lung cancer: from tissue testing to liquid biopsy


The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

This article is being featured as part of our Spotlight on circulating tumor cells – visit our Spotlight homepage for more information.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.